2023
DOI: 10.1016/j.jhepr.2023.100763
|View full text |Cite
|
Sign up to set email alerts
|

Immuno-genomic-radiomics to predict response of biliary tract cancer to camrelizumab plus GEMOX in a single-arm phase II trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 24 publications
0
1
0
Order By: Relevance
“…Fifthly, data-driven radiomics methods are inherently challenging to interpret in the context of their underlying biological and immunological mechanisms, which constrains the explainability and broader clinical adoption of radiomics models. In the future, there are many possibilities for exploration in the radiomics practice of schistosomiasis-related liver diseases [40,[43][44][45][46][47][48][49].…”
Section: Plos Neglected Tropical Diseasesmentioning
confidence: 99%
“…Fifthly, data-driven radiomics methods are inherently challenging to interpret in the context of their underlying biological and immunological mechanisms, which constrains the explainability and broader clinical adoption of radiomics models. In the future, there are many possibilities for exploration in the radiomics practice of schistosomiasis-related liver diseases [40,[43][44][45][46][47][48][49].…”
Section: Plos Neglected Tropical Diseasesmentioning
confidence: 99%